Pharmaceuticals

Shaping a resilient, nature positive pharmaceutical industry​

Pharmaceutical companies rely on nature for critical resources, from active ingredients and raw materials to ecosystem services that sustain production. As global biodiversity declines and ecosystems degrade, risks to supply continuity, R&D pipelines, and regulatory compliance can become increasingly material. These can in turn jeopardise business resilience, investments, and reputation. In addition to the business risks that nature poses, significant opportunities also exist: by integrating nature into strategic planning, forward-thinking companies can mitigate risk and unlock value through innovation, efficiency, stakeholder trust, and long-term sustainability.

The Biodiversity Consultancy works with pharmaceutical companies across the full value chain to identify dependencies, assess risks, and integrate biodiversity into business strategy, operations, and reporting. We help businesses align with leading frameworks such as the Science Based Targets Network (SBTN) and the Taskforce on Nature-related Financial Disclosures (TNFD) and support credible, science-based action on nature.​

We help businesses build resilient supply chains, securing access to natural resources, and strengthening long-term business performance.​